Polpharma Biologics announces global commercialization deal for biosimilar natalizumab, a key multiple sclerosis medicine.
Press release 03.09.2019
- Published:
- written by: Polpharma Biologics
Related news
Other news related to this topic that may be of interest to you
Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar
Zurich, Switzerland – October 21, 2025 – Polpharma Biologics today announced Ranivisio® PFS (ranibizumab...
Polpharma Biologics is splitting its operations into two independent companies
Polpharma Biologics is splitting its operations into two independent companies, each with a clear focus...
Polpharma Biologics and MS Pharma sign licensing agreements for proposed vedolizumab (PB016), ocrelizumab (PB018) and guselkumab (PB019) biosimilars.
Amsterdam, Gdańsk – September 2nd, 2025 – Polpharma Biologics S.A. (“Polpharma Biologics”), specialized...
Polpharma Biologics and Fresenius Kabi sign licensing agreement for proposed vedolizumab biosimilar PB016
Amsterdam, Gdańsk – August 5, 2025 – Polpharma Biologics S.A. (“Polpharma Biologics”) announces a global...